Lunai Bioworks granted U.S. patent for AI drug discovery system

Lunai Bioworks (LNAI) announced the issuance of a U.S. patent titled “Methods, Systems, and Frameworks for Debiasing Data in Drug Discovery Predictions.” The newly issued patent protects the foundational first step of Lunai’s proprietary closed-loop disease reverse engineering platform, multimodal data standardization and structural bias removal prior to predictive modeling. Lunai’s patented architecture systematically detects, standardizes, and removes structural bias across multimodal inputs before downstream artificial intelligence modeling begins. By protecting this core data layer, Lunai aims to strengthen its ability to accurately identify biologically coherent patient subtypes and trace those subtypes to the gene networks most strongly associated with each disease type.